In the press – BioProcess International discussion


The AutoloMATE platform was highlighted as a solution to facilitating manufacturing scale-up as part of the discussion led by BioProcess International around innovative systems being deployed within the Cell and Gene therapy manufacturing space – Preparing for Process Improvements: Discussions of the Cell Therapy Industry’s Supply Chain, Automation, and Control Needs.

Our COO, Kwok Pang, spoke about the CGT industry’s need for digitisation and better data management.

“Why are digital solutions needed for cell therapy manufacturing? I’ve been in advanced therapies for the past 18 years, and I’ve seen the CGT industry’s growing need for scaling to large commercial scales and the need for better tools for managing data generated from those processes. Autologous therapy manufacturing, for example, in which an entire batch is made for one patient, generates a lot of critical manufacturing data. That data are generated for every patient.

Two years ago, Autolomous was founded to tackle data management challenges related to scaling up CGT processes. We commercialised an electronic batch manufacturing solution that helps to link process-generated data for all types of complex manufacturing workflows. Our AutoloMATE system is supporting a dendritic-cell vaccine workflow, a chimeric antigen receptor (CAR) T-cell workflow, an allogeneic natural-killer (NK) cell workflow, and an induced pluripotent stem cell (IPSC) workflow with a US contract development and manufacturing organisation. In all environments, data must be managed to reassure regulators that manufacturing scale-up happens in a controlled manner with full auditability. That’s where our digital solutions come into play.”